ABSTRACT
OBJECTIVE: To assess whether a high intake of oral iron would increase the effect of recombinant human erythropoietin (rHuEPO) on hemoglobin synthesis. METHODS: We studied 30 preterm infants (gestational age 29+/-1.8 weeks, birth weight 1161+/-200 g, at age of 28+/-10 days) who were randomly assigned to receive either 8 mg/kg per day (n=15) or 16 mg/kg per day of oral iron during a course of rHuEPO therapy (900 microg/kg per week) for a duration of 4 weeks. Both groups were comparable in regard to clinical and laboratory data at the time of enrollment. RESULTS: rHuEPO caused a significant increase in reticulocyte count in the low- and high-dose iron groups, 17.1+/-5.3 to 34.7+/-9.2 and 16.3+/-3.3 to 42.5+/-5.6 (10(9)/l), respectively (p<0.05). However, in both groups, hematocrit values remained stable at the end of the study as compared to baseline (0.35+/-0.03% vs. 0.30+/-0.03%, 0.35+/-0.05% vs. 0.30+/-0.03%, NS) and in both groups there was a comparable and significant decrease in ferritin level (259+/-109 to 101+/-40 and 168+/-54 to 69+/-38 microg/l, respectively; p<0.01). The rates of bloody stools without any evidence of necrotizing enterocolitis were not significantly different between the two treatment groups (1/15 vs. 4/15, NS). CONCLUSION: We conclude that a higher dose (16 mg/kg per day) of oral iron is not more beneficial when compared to a lower dose (8 mg/kg per day) during rHuEPO therapy for anemia of prematurity. Further studies will define the optimal dosage and route of administration of iron supplementation during rHuEPO therapy.
Subject(s)
Anemia, Neonatal/therapy , Erythropoietin/therapeutic use , Infant, Premature, Diseases/therapy , Iron/administration & dosage , Administration, Oral , Analysis of Variance , Anemia, Neonatal/blood , Drug Synergism , Female , Ferritins/blood , Hematocrit , Humans , Infant, Newborn , Infant, Premature, Diseases/blood , Male , Recombinant ProteinsABSTRACT
A pulmonary cyst appeared in a growing preterm infant. The presumptive diagnosis was septic pulmonary embolism associated with the central venous catheter. The infant was successfully treated with antibiotic therapy and removal of the central venous catheter.
Subject(s)
Cysts/diagnostic imaging , Infant, Premature, Diseases/diagnostic imaging , Pulmonary Embolism/diagnostic imaging , Staphylococcal Infections/diagnostic imaging , Staphylococcus epidermidis , Catheterization, Central Venous , Humans , Infant, Newborn , Male , Tomography, X-Ray ComputedSubject(s)
Cysts/diagnosis , Lung Diseases/diagnosis , Cysts/pathology , Cysts/surgery , Female , Humans , Hypertension, Pulmonary/complications , Hypertension, Pulmonary/diagnosis , Infant, Newborn , Lung Diseases/pathology , Lung Diseases/surgery , Pneumothorax/complications , Recurrence , Respiration, Artificial , Respiratory Insufficiency/etiology , Respiratory Insufficiency/therapy , Tomography, X-Ray ComputedABSTRACT
UNLABELLED: The diagnosis and evaluation of perinatal asphyxia can be problematic and objective means of assessing its severity are lacking. To study the validity of urinary uric acid as a marker of the degree of perinatal asphyxia, the ratio of urinary uric acid to creatinine (UA/Cr) in urine specimens obtained after birth was measured in two groups of infants. Eighteen term infants with Apgar scores < or = 5 at 5 min and/or an umbilical cord blood pH < or = 7.2, and a base deficit > or = 12 meq/l were compared to 50 healthy controls. The severity of the perinatal asphyxia was determined by using an ASPHYXIA SCORE. The UA/Cr was higher in the asphyxiated group when compared to controls. (2.06 +/- 1.12, vs. 0.64 +/- 0.48; P < 0.001). Within the perinatal asphyxia group, a significant correlation was found between the UA/Cr ratio and the asphyxia score. (r = 0.86, P < 0.01). CONCLUSION: Infants with perinatal asphyxia have a significantly higher urinary UA/Cr ratio. This may be used as an indicator of the severity of perinatal asphyxia.
